FDA Approves New Treatment for Adults with Relapsed or Refractory Large-B-Cell Lymphoma
WASHINGTON, D.C. — The U.S. Food and Drug Administration recently approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who …
Read More